9月21日，荣昌生物盘中上涨5.35%，报78.65港元，成交额6617.6万港元。
消息面上，公司与艾伯维联合开发的PD-1/VEGF双特异性抗体RC148近日在世界肺癌大会（WCLC 2026）以口头报告形式公布一线治疗非小细胞肺癌Ⅰb期数据，鳞癌队列客观缓解率达90.0%，非鳞癌队列达75.9%，PD-L1阴性亚组同样展现深度缓解，同步展示了鳞状非小细胞肺癌Ⅲ期临床试验方案。多家机构随后上调目标价，其中里昂将目标价升至144.8港元，花旗升至127.7港元，均维持买入类评级。此外，公司上半年营收58.53亿元，同比增长433.11%，净利润46.62亿元实现扭亏为盈，基本面持续改善对股价形成支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.